Novo Nordisk CEO Maziar Mike Doustdar on a second quarter earnings call argued that failure is par for the course in the drug development business. The Danish pharma is focused on building out its pipeline to move past recent clinical roadblocks.

Original title: “Novo CEO sees innovation as a matter of survival amid pipeline setbacks”

BioSpace NextGen honorees made up one-third of the U.S. biotechs that have publicly debuted in 2026. Most are looking for biopharma professionals to join their teams.

Original title: “5 NextGen winners who went public this year (and which ones are hiring)”

Pharma is definitely interested in making more deals. But what biotechs will come under the magnifying glass? BioSpace takes a look at companies that analysts see as near-term targets for buyouts.

Original title: “4 potential biotech M&A targets, plus a pretty sure bet from J&J”

The Centers for Disease Control and Prevention (CDC), located within the Department of Health and Human Services (HHS), announces one award to fund Fundacion Mexico-Estados Unidos Para La Ciencia, A.C. for approximately $800,000 in Federal Fiscal Year 2026, subject to the availability of funds. Funding amounts for years 2-5 will be set at continuation.

Original title: “Notice of Award of a Single Source Grant To Fund Fundacion Mexico-Estados Unidos Para La Ciencia, A.C.”

The Centers for Disease Control and Prevention (CDC), located within the Department of Health and Human Services (HHS), announces one award to fund HJF Medical Research International, Inc., Kenya, for approximately $1,000,000 in Federal Fiscal Year 2026, subject to the availability of funds. Funding amounts for years 2-5 will be set at continuation.

Original title: “Notice of Award of a Single-Source Grant To Fund HJF Medical Research International, Inc., Kenya”

The Centers for Disease Control and Prevention (CDC), located within the Department of Health and Human Services (HHS), announces one award to fund Fondacioni SECID, Balkan Region, for approximately $800,000 in Federal Fiscal Year 2026, subject to the availability of funds. Funding amounts for years 2-5 will be set at continuation.

Original title: “Notice of Award of a Single-Source Grant To Fund Fondacioni SECID, Balkan Region”

The Centers for Disease Control and Prevention (CDC), located within the Department of Health and Human Services (HHS), announces one award to fund The Task Force for Global Health for approximately $4,000,000, in Federal Fiscal Year 2026, subject to the availability of funds. Funding amounts for years 2-5 will be set at continuation.

Original title: “Notice of Award of a Single Source Cooperative Agreement To Fund Task Force for Global Health, Inc.”

The Centers for Disease Control and Prevention (CDC), located within the Department of Health and Human Services (HHS), announces one award to fund the Universidad Peruana Cayetano Heredia for approximately $600,000 in Federal Fiscal Year 2026, subject to the availability of funds. Funding amounts for years 2-5 will be set at continuation.

Original title: “Notice of Award of a Single-Source Grant To Fund Universidad Peruana Cayetano Heredia”

Novo Nordisk’s shares fell 6% on Tuesday afternoon after its second quarter earnings report showed a slight miss for the Wegovy pill vs. consensus.

Original title: “Novo dips 6% on Wegovy pill stumble despite Q2 earnings beat”

Asked on a second quarter earnings call if Pfizer could direct more money to M&A amid a feeding frenzy across the pharma industry, CEO Albert Bourla defended his strategy.

Original title: “Pfizer CEO defends $7B bolt-on M&A strategy as peers rush to buy”

Despite another strong earnings report, analysts warned that upcoming cystic fibrosis data from Sionna Therapeutics "looms large" over Vertex.

Original title: “Vertex’s biggest overhang: a rival 50 times smaller”

The anti-TL1A antibody from Merck's 2023 Prometheus buy delivered positive mid-stage results in a skin condition but failed in a certain type of lung disease, the Big Pharma revealed alongside second-quarter earnings.

Original title: “Merck’s $10.8B Prometheus deal delivers another win—plus a Phase 2b miss”